Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.
Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators; Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine EU, Aminoff MJ, Bodis-Wollner IG, Boyd J, Cambi F, Chou K, Christine CW, Cines M, Dahodwala N, Derwent L, Dewey RB Jr, Hawthorne K, Houghton DJ, Kamp C, Leehey M, Lew MF, Liang GS, Luo ST, Mari Z, Morgan JC, Parashos S, Pérez A, Petrovitch H, Rajan S, Reichwein S, Roth JT, Schneider JS, Shannon KM, Simon DK, Simuni T, Singer C, Sudarsky L, Tanner CM, Umeh CC, Williams K, Wills AM. Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, et al. Among authors: liang gs. JAMA. 2015 Feb 10;313(6):584-93. doi: 10.1001/jama.2015.120. JAMA. 2015. PMID: 25668262 Free PMC article. Clinical Trial.
Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.
Parashos SA, Swearingen CJ, Biglan KM, Bodis-Wollner I, Liang GS, Ross GW, Tilley BC, Shulman LM; NET-PD Investigators. Parashos SA, et al. Among authors: liang gs. Arch Neurol. 2009 Sep;66(9):1099-104. doi: 10.1001/archneurol.2009.159. Epub 2009 Jul 13. Arch Neurol. 2009. PMID: 19597081 Free PMC article. Clinical Trial.
Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease.
Tetrud J, Nausieda P, Kreitzman D, Liang GS, Nieves A, Duker AP, Hauser RA, Farbman ES, Ellenbogen A, Hsu A, Kell S, Khanna S, Rubens R, Gupta S. Tetrud J, et al. Among authors: liang gs. J Neurol Sci. 2017 Feb 15;373:116-123. doi: 10.1016/j.jns.2016.11.047. Epub 2016 Nov 23. J Neurol Sci. 2017. PMID: 28131167 Free article. Clinical Trial.
Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort.
Chou KL, Elm JJ, Wielinski CL, Simon DK, Aminoff MJ, Christine CW, Liang GS, Hauser RA, Sudarsky L, Umeh CC, Voss T, Juncos J, Fang JY, Boyd JT, Bodis-Wollner I, Mari Z, Morgan JC, Wills AM, Lee SL, Parashos SA; NINDS NET-PD Investigators. Chou KL, et al. Among authors: liang gs. J Neurol Sci. 2017 Jun 15;377:137-143. doi: 10.1016/j.jns.2017.04.011. Epub 2017 Apr 11. J Neurol Sci. 2017. PMID: 28477684 Free PMC article. Clinical Trial.
A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia.
Marder SR, Singer C, Lindenmayer JP, Tanner CM, Comella CL, Verghese C, Jimenez R, Liang GS, Burke J, OʼBrien CF. Marder SR, et al. Among authors: liang gs. J Clin Psychopharmacol. 2019 Nov/Dec;39(6):620-627. doi: 10.1097/JCP.0000000000001111. J Clin Psychopharmacol. 2019. PMID: 31688452 Clinical Trial.
39 results